MUNICH, GERMANY — Results so far from three studies of the cholesterol-lowering drug Vytorin are not enough to prove or rule out a possible link to a higher risk of cancer, so the drug should be used ...

TRENTON (AP) - Results of a preliminary analysis of the just-completed study showed Vytorin, marketed jointly by Merck & Co. and Schering-Plough Corp., was no better than placebo at lowering the risk ...

CHICAGO Millions of Americans already take the drug or one of its components, Zetia. But doctors were stunned to learn that Vytorin failed to improve heart disease even though it worked as intended to ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. Vytorin, the combination drug prescribed to lower cholesterol, sustained ...

Trenton, N.J. -- The Food and Drug Administration said Thursday patients should not stop taking Vytorin or other cholesterol-lowering drugs, based on its just-completed review of a controversial study ...

Cholesterol drug Vytorin--and makers Merck and Schering-Plough--have been under fire for months since a study suggested that the expensive combo med works no better than much less costly Zocor. Things ...

What would a new year be without a full-blown pharmaceutical controversy? Last summer there were black-box warnings for Avandia and Actos, two diabetes drugs associated with heart failure. In the fall ...

NEW ORLEANS (Reuters) - Researchers attempted on Wednesday to calm concerns about the potential cancer risks of cholesterol fighters Vytorin and Zetia, while others urged caution in prescribing the ...

NEWARK (CN) - In a shareholder's class action that neatly summarizes complaints about Schering-Plough Corp.'s sales of its cholesterol drugs Zetia and Vytorin, the Arkansas Teacher Retirement System ...